Mei Ri Jing Ji Xin Wen·2026-01-01 04:53Group 1 - MiniMax has officially launched its IPO in Hong Kong, with a total of 25.39 million shares to be issued at a price range of HKD 151 to HKD 165 per share, aiming to raise funds for AI model and product development [1] - MiniMax is recognized as one of the "top four global full-modal companies," with a user base exceeding 200 million, covering both B2C and B2B AI native products [1] Group 2 - Rebio Biotech has initiated its IPO in Hong Kong, planning to issue 27.49 million H-shares at a price of HKD 57.97 per share, with 10% allocated for Hong Kong and 90% for international sales [2] - The company focuses on small nucleic acid drug research, particularly in siRNA therapies, with its core product RBD4059 aimed at treating thrombotic diseases [2] Group 3 - BlueFocus Communication Group has submitted its second listing application to the Hong Kong Stock Exchange, with a focus on providing technology-driven marketing services across various industries [3] - The company aims to leverage its position as a leading marketing firm in China to enhance its global and AI-native business through the upcoming IPO [3] Group 4 - Longqi Technology has passed the listing hearing at the Hong Kong Stock Exchange, being recognized as a leading provider of smart products and services, with significant market shares in both consumer electronics and smartphone ODM sectors [4] - The company holds a 22.4% market share in the global consumer electronics ODM market and a 32.6% share in the smartphone ODM market, indicating its strong industry position [4]